Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction

NCT06536309 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06536309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06536309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 4
Overall status
Withdrawn
Start date
August 27, 2026
Completion date
August 27, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, myocardial fibrosis